Atrasentan in IgA nephropathy
Endothelin-1 is a vasoactive peptide implicated in the pathophysiology of IgA nephropathy
- binding of endothelin-1 to the endothelin type A receptor in the kidney causes endothelial and podocyte damage, mesangial expansion, and tubular inflammation in experimental models of IgA nephropathy
- atrasentan, an endothelin receptor antagonist (ERA), decreased albuminuria and reduced the risk of kidney failure in the Study of Diabetic Nephropathy with Atrasentan (SONAR) trial (1)
- in a prespecified interim analysis of the ALIGN trial, atrasentan resulted in a significant and clinically meaningful reduction in proteinuria as compared with placebo in patients with IgA nephropathy (2)
Reference:
- Heerspink HJL et al ; SONAR Committees and Investigators .Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): A double-blind, randomised, placebo-controlled trial. Lancet 393: 1937–1947, 2019
- Heerspink HJL et al; for the ALIGN Study Investigators. Atrasentan in Patients with IgA Nephropathy. NEJM October 25th 2024.
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.